NASDAQ:NYMX - Nymox Pharmaceutical Stock Price, Forecast & News

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Nymox Pharmaceutical Corp (NASDAQ:NYMX) announced its quarterly earnings data on Wednesday, November, 13th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.04 million for the quarter. Nymox Pharmaceutical had a negative net margin of 12,217.59% and a negative return on equity of 174.16%. View Nymox Pharmaceutical's Earnings History.

Nymox Pharmaceutical is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Nymox Pharmaceutical.

News articles about NYMX stock have been trending somewhat positive recently, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nymox Pharmaceutical earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Nymox Pharmaceutical.

Some companies that are related to Nymox Pharmaceutical include Heska (HSKA), Intellia Therapeutics (NTLA), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Arca Biopharma (ABIO), GeneNews (GNWSF), Achieve Life Sciences (ACHV) and Akers Biosciences (AKER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), Rigel Pharmaceuticals (RIGL) and CTI BioPharma (CTIC).

Nymox Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.06%). Company insiders that own Nymox Pharmaceutical stock include Erik Danielsen, James George Robinson, Paul Averback and Randall J Lanham. View Institutional Ownership Trends for Nymox Pharmaceutical.

NYMX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Nymox Pharmaceutical.

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NYMX stock can currently be purchased for approximately $3.08.

Nymox Pharmaceutical has a market capitalization of $215.50 million and generates $300,000.00 in revenue each year. View Additional Information About Nymox Pharmaceutical.

The official website for Nymox Pharmaceutical is http://www.nymox.com/.

Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, ST. LAURENT A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]